COMMUNIQUÉS West-GlobeNewswire

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
16/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Dr. James Chim to Receive Asian Myeloma Network Distinguished Service Award at the 9th AMN Summit in Nagoya
16/10/2025
International Myeloma Foundation (IMF) to hold AMN Awards Ceremony at the 9th AMN Summit in Nagoya, Japan on Saturday, October 18. NAGOYA, Japan, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation ( [...]
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
16/10/2025
First-time presentation examining bone outcomes in early postmenopausal women JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein [...]
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
16/10/2025
Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant [...]
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
16/10/2025
Will Showcase Latest Fertility Solutions SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more [...]
Omada Health to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
16/10/2025
SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thursday, November 6, [...]
SAFE - Réalisation définitive de la réduction de capital non motivée par des pertes par voie de réduction de la valeur nominale des actions
16/10/2025
Réalisation définitive de la réduction de capital non motivée par des pertes par voie de réduction de la valeur nominale des actions Fleurieux-sur-l’Arbresle – France – 16 octobre 2025 - Safe (FR001400ZU25 – ALSAF) (la [...]
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
16/10/2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled [...]
Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial
16/10/2025
Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments in refractory [...]
Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques.
16/10/2025
Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques. Le tour de table est mené par Bpifrance, [...]
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
16/10/2025
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led by Bpifrance with co-leads Kurma Partners, Andera Partners and [...]
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
16/10/2025
APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today [...]
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
16/10/2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025
16/10/2025
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read platforms. Leveraging Roche’s SBX [...]
Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025
16/10/2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports 77% year-over-year increase for the first nine months of 2025 Financial [...]
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
16/10/2025
In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years 1 eGFR is key marker of [...]
The Board of Directors maintains its recommendation in supplementary statement in respect of the improved takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
16/10/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
16/10/2025
Kay was instrumental in driving the successful development and commercialization of Xofigo ® , the first and only approved alpha therapy to date SYDNEY, Australia - October 16, 2025 – AdvanCell, a clinical-stage [...]
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
16/10/2025
Covers low tumor burden “watch-and-wait” setting, an unmet medical need Registrational Phase 3 watch-and-wait to start in 2026 EO2463 has broad potential to treat hemato-oncology indications Paris, France – 16 OCTOBER, [...]

Pages